Articles On Telix Pharmaceuticals (ASX:TLX)

Telix (ASX:TLX) has officially opened its radiopharmaceutical production facility in Brussels South (Seneffe), in the Wallonia region of Belgium.

Australia’s second-largest biotechnology company by revenue behind CSL (ASX: CSL), Telix Pharmaceuticals (ASX: TLX) opened a world-class radiopharmaceutical nuclear medicine facility in Belgium on Thursday. The $21 million facility will se...

Telix has unveiled its new, state-of-art radiopharmaceutical facility in Brussels South as part of its first stage investment of €14.1 million ($A21.2 million)    Located in Walloon’s ‘Radiopharma Valley’ the facility will be a central...

MELBOURNE, Australia, June 6, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare C...

The final day of the trading week saw the ASX finish in the green up 0.48 per cent. This comes after the US senate voted to suspend the country’s debt ceiling until 2025, avoiding a potentially catastrophic default. In the green U...

After starting the day off on the wrong foot, the S&P/ASX 200 Index (ASX: XJO) tumbled even further this afternoon to close the day 1.48% lower at 7,102.8 points. The apparent driver of its tumble was the latest Aussie inflation figur...

The S&P/ASX 200 Index (ASX: XJO) traded in the red for much of Tuesday, ending the session 0.11% lower at 7,209.3 points. It came on the back of various public holidays in the United States, the United Kingdom, and Germany on Monday. T...

It has been a great start to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is up 1.1% to 7,231.2 points. Four ASX shares that have failed to follow the market higher today are listed below. Her...

June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the p...

The S&P/ASX 200 Index (ASX: XJO) tumbled on Thursday, falling 1.05% to close at 7,138.2 points. The market’s suffering came amid continued concerns of the United States’ rapidly approaching debt ceiling, as my Fool colleague Bernd...

World Overnight SPI Overnight 7241.00 – 35.00 – 0.48% S&P ASX 200 7259.90 – 3.40 – 0.05% S&P500 4145.58 – 47.05 – 1.12% Nasdaq Comp 12560.25 – 160.53 – 1.26% DJIA 33055.51 – 231.07 – 0.69% S&P500 VIX 18.53 + 1.32 7...

After spending all day in the green, the S&P/ASX 200 Index (ASX: XJO) posted a last-minute fall on Tuesday, dropping 0.05% to close at 7,259.9 points. It followed a mixed performance on Wall Street overnight. The Dow Jones Industrial...

The S&P/ASX 200 Index (ASX: XJO) is in the green on Tuesday, thanks in part to three stocks each soaring to new all-time record highs. So, what’s been going right for the trio lately? Let’s take a look. 3 ASX 200 shares reaching re...

The S&P/ASX 200 Index (ASX: XJO) spent Tuesday in the red, closing the day 0.45% lower at 7,234.7 points. And there were plenty of sectors weighing it down. The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) was its worst performer....

Maybe you are sick of hearing this, but it doesn’t make it any less true: it’s a turbulent time for ASX shares at the moment. With much of the world still struggling with both high inflation and steep interest rate rises, it’s touch-and-go...

The S&P/ASX 200 Index (ASX: XJO) slipped lower once more on Thursday, falling 0.05% to close at 7,251.9 points. Weighing it down was the S&P/ASX 200 Materials Index (ASX: XMJ), which slumped 0.4% despite a ripper performance from...

The S&P/ASX 200 Index (ASX: XJO) slumped on Wednesday, dropping 0.12% to close at 7,255.7 points. Its day in the red came on the back of the 2023 federal budget, delivered on Tuesday night. It included $14.6 billion of spending aimed a...

S&P/ASX 300 Index (ASX: XKO) shares have returned an average of 18.8% over the past five years. Of course, some stocks have exceeded those gains while others have lost value over this time. Below, we look at three ASX 300 shares that w...

Telix (ASX:TLX) has agreed with Bayer to supply its Illuccix for a Phase 3 ARASTEP study investigating the efficacy of the German company's Nubeqa (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer...

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the prepar...

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, k...

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month. The Telix Pharmaceuticals share price has soared 53% from $7.01 at market close on 3 April to $10.745 at the time of writing. For perspective, the S&am...

The S&P/ASX 200 Index (ASX: XJO) plummeted on Tuesday, dropping 0.92% to finish the session at 7,267.4 points. Its day in the red came amid the Reserve Bank of Australia (RBA) board’s May meeting, wherein it hiked interest rates once...

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illucc...

The ASX jumped half a percent, tracking moves in New York on Friday Three major decisions by central banks this week Judo Capital upgrades its net interest margin guidance for H2    The ASX 200 index rose to by 0.5% on Tuesday as it track...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a positive fashion. In afternoon trade, the benchmark index is currently up 0.5% to 7,343.3 points. Four ASX shares that are climbing more than most today are listed below. Her...

Telix Pharmaceuticals (TLX) reveals new “positive” results from its phase III ZIRCON study of its TLX250-CDx imaging agent in clear cell renal cell carcinoma (ccRCC) TLX says the study shows the “high value” of its agent in detecting cc...

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuxi...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Telix Pharmaceuticals (TLX) expands its artificial intelligence (AI) capability through the acquisition of Vienna-based Dedicaid, a spin-off of Medical University Vienna Telix says Dedicaid’s core asset, a clinical decision support softw...

Stock in S&P/ASX 200 Index (ASX: XJO) biopharma company Telix Pharmaceuticals Ltd (ASX: TLX) is in the red on news of a major artificial intelligence (AI) acquisition. The developer of diagnostic and therapeutic radiopharmaceuticals ha...

The ASX is on Thursday expected to follow the US Dow Jones index, which declined overnight following another slump in the banking sector. The dip comes from troubles surrounding the First Republic Bank, which has seen its shares fall mor...

After starting off deep in the red, the S&P/ASX 200 Index (ASX: XJO) regained some ground to close 0.08% lower at 7,316.3 points. Its wobbly performance came amid the release of the latest Australian consumer price index (CPI) data, co...

The S&P/ASX 200 Index (ASX: XJO) closed the week in the red, falling 0.43% in Friday’s session to close at 7,330.4 points. That leaves it 0.42% lower than it was this time last week. Weighing the index down today were its two largest...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is on course to end the week with a decline. In afternoon trade, the benchmark index is down 0.4% to 7,335.4 points. Four ASX shares that are not letting that hol...

ASX health stocks fall 0.32% in the past five days, despite rise in broader markets Neuren Pharmaceutical announces its DAYBUE drug officially available in US to treat Rett Syndrome Impedimed quarterly results in line with expectations wit...

Highlights: The Australian benchmark index S&P/ASX 200 index, has decreased by 2.64% in the last one-year period. On 20 April, SILK Australia Limited (ASX: SLA) managed to hit its 52-week, closing the trading session at AU$3.000, i...

The S&P/ASX 200 Index (ASX: XJO) traded relatively flat for most of Thursday, finishing the session 0.04% lower at 7,362.2 points. It came on a dismal performance by the S&P/ASX 200 Materials Index (ASX: XMJ). The mining sector tu...

Australian radiopharmaceutical company Telix (ASX:TLX) has delivered its first $100 million revenue quarter with soaring growth in the US.

The ASX ended the day in the green, but Asian markets didn’t quite cross the line. The ASX 200 closed up 5.3 points or 0.07 per cent to 7365.5 points. In the green Healthcare stock Telix Pharmaceuticals (TLX) was the top-performing...

The S&P/ASX 200 Index (ASX: XJO) had a rocky session on Wednesday, ultimately closing 0.07% higher at 7,365.5 points. Today’s top-performing sector was the S&P/ASX 200 Materials Index (ASX: XMJ). It soared 1.1%. Unfortunately, it...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a tiny gain. At the time of writing, the benchmark index is up a fraction to 7,362.2 points. Four ASX shares that are climbing more than most today are listed...

ASX 200 stock Telix Pharmaceuticals Ltd (ASX: TLX) has been having a top run on the market lately. Telix shares have risen nearly 32% in a month and are currently fetching $9.30. In today’s trade, Telix shares are up 4.44%. In contrast,...

Trawling through shares in the S&P/ASX 200 Index (ASX: XJO), we can at times forget what actually creates wealth for shareholders in the long run. While the share price moves arbitrarily in the short term, the decisions on how to inve...

The ASX 200 ended Tuesday 0.3 per cent lower at 7360 points after struggling to stage a midday comeback. Minutes from the Reserve Bank’s last meeting revealed an April rates hike was very much on the cards before its decision to pause....

ShareCafeASX recoups some earlier losses to close 0.29% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.29 per cent lower at 7,360.20, primarily due to a 1.9 per cent decline in the energy sector, with Woodside (ASX:W...

The S&P/ASX 200 Index (ASX: XJO) traded in the red on Tuesday, falling 0.29% to close at 7,360.2 points. Weighing it down was the S&P/ASX 200 Energy Index (ASX: XEJ). The energy sector fell 1.9% on the back of a rough night for oil...

The ASX slumped by 0.4% today as the RBA released its April minutes Core Lithium jumped 8pc after increasing its MRE BlackRock ditched its 60/40 strategy   Local shares fell 0.4% on Tuesday after the RBA minutes revealed the central bank...

It’s been a pretty depressing day for ASX shares and the All Ordinaries Index (ASX: XAO) so far this Tuesday. At the time of writing, the All Ords has slipped by 0.4%, dragging the Index back below 7,550 points. But not all All Ords shares...

Telix (ASX:TLX) says olaratumab, an antibody licensed from Eli Lilly, has demonstrated proof-of-concept in a preclinical study investigating its delivery of diagnostic and therapeutic radiation to tumours.